{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:10:39Z","timestamp":1781543439427,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T00:00:00Z","timestamp":1478304000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00213-016-4445-0","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T01:51:45Z","timestamp":1478310705000},"page":"3-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study"],"prefix":"10.1007","volume":"234","author":[{"given":"Andreas","family":"Schreiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaf","family":"Caspi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bergmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Cherubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Keim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Pinchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Schuepbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajid","family":"Suleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Hargarter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,5]]},"reference":[{"key":"4445_CR1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.schres.2014.04.024","volume":"156","author":"L Alphs","year":"2014","unstructured":"Alphs L, Schooler N, Lauriello J (2014) How study designs influence comparative effectiveness outcomes: the case of oral versus long-acting injectable antipsychotic treatments for schizophrenia. Schizophr Res 156:228\u2013232","journal-title":"Schizophr Res"},{"key":"4445_CR2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL et al (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12","journal-title":"Health Qual Life Outcomes"},{"key":"4445_CR3","doi-asserted-by":"crossref","unstructured":"Barnes TR (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxford, England) 25: 567\u2013620","DOI":"10.1177\/0269881110391123"},{"key":"4445_CR4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40261-012-0047-8","volume":"33","author":"F Ca\u00f1as","year":"2013","unstructured":"Ca\u00f1as F, Alptekin K, Azorin JM et al (2013) Improving treatment adherence in your patients with schizophrenia: the STAY initiative. Clin Drug Investig 33:97\u2013107","journal-title":"Clin Drug Investig"},{"key":"4445_CR5","doi-asserted-by":"crossref","unstructured":"Carey KB, Cocco KM, Simons JS (1996) Concurrent validity of clinicians\u2019 ratings of substance abuse among psychiatric outpatients. Psychiatr Serv (Washington, DC) 47: 842\u20137","DOI":"10.1176\/ps.47.8.842"},{"key":"4445_CR6","doi-asserted-by":"crossref","unstructured":"Chouinard G, Margolese HC (2005) Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 76:247\u2013265","DOI":"10.1016\/j.schres.2005.02.013"},{"key":"4445_CR7","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/070674370204700909","volume":"47","author":"PE Cook","year":"2002","unstructured":"Cook PE, Goldberg JO, Van Lieshout RJ (2002) Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Can J Psychiatr 47:870\u2013874","journal-title":"Can J Psychiatr"},{"key":"4445_CR8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","volume":"60","author":"JM Davis","year":"2003","unstructured":"Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553\u2013564","journal-title":"Arch Gen Psychiatry"},{"key":"4445_CR9","first-page":"99","volume":"12","author":"A Bartolomeis de","year":"2016","unstructured":"de Bartolomeis A, Fagiolini A, Vaggi M et al (2016) Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics. Neuropsychiatr Dis Treat 12:99\u2013108","journal-title":"Neuropsychiatr Dis Treat"},{"key":"4445_CR10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/11634500-000000000-00000","volume":"26","author":"M De Hert","year":"2012","unstructured":"De Hert M, Yu W, Detraux J et al (2012) Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS drugs 26:733\u2013759","journal-title":"CNS drugs"},{"key":"4445_CR11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","volume":"25","author":"S Gopal","year":"2010","unstructured":"Gopal S, Hough DW, Xu H et al (2010) Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 25:247\u2013256","journal-title":"Int Clin Psychopharmacol"},{"key":"4445_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2014.11.006","volume":"58","author":"L Hargarter","year":"2015","unstructured":"Hargarter L, Cherubin P, Bergmans P et al (2015) Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Prog Neuro-Psychopharmacol Biol Psychiatry 58:1\u20137","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"4445_CR13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","volume":"14","author":"A Hasan","year":"2013","unstructured":"Hasan A, Falkai P, Wobrock T et al (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 14:2\u201344","journal-title":"World J Biol Psychiatry"},{"key":"4445_CR14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/2045125312474019","volume":"3","author":"K Higashi","year":"2013","unstructured":"Higashi K, Medic G, Littlewood KJ et al (2013) Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 3:200\u2013218","journal-title":"Ther Adv Psychopharmacol"},{"key":"4445_CR15","unstructured":"Janssen Cilag (2015) Paliperidone palmitate summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002105\/WC500103317.pdf (Accessed October 2016)"},{"key":"4445_CR16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.5414\/CPP48383","volume":"48","author":"MP Jones","year":"2010","unstructured":"Jones MP, Nicholl D, Trakas K (2010) Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Int J Clin Pharmacol Ther 48:383\u2013399","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4445_CR17","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H et al (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085\u20131097","journal-title":"Lancet"},{"key":"4445_CR18","doi-asserted-by":"crossref","unstructured":"Kirson NY, Weiden PJ, Yermakov S et al (2013) Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 74: 568\u201375","DOI":"10.4088\/JCP.12r08167"},{"key":"4445_CR19","doi-asserted-by":"crossref","unstructured":"Kishimoto T, Nitta M, Borenstein M et al (2013) Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74: 957\u201365","DOI":"10.4088\/JCP.13r08440"},{"key":"4445_CR20","doi-asserted-by":"crossref","unstructured":"Kishimoto T, Robenzadeh A, Leucht C et al (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40:192\u2013213","DOI":"10.1093\/schbul\/sbs150"},{"key":"4445_CR21","first-page":"31","volume":"2","author":"CM Kozma","year":"2009","unstructured":"Kozma CM, Weiden PJ (2009) Partial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database. Am Health Drug Benefits 2:31\u201338","journal-title":"Am Health Drug Benefits"},{"key":"4445_CR22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/WNF.0b013e31815cba78","volume":"31","author":"I Lerma-Carrillo","year":"2008","unstructured":"Lerma-Carrillo I, de Pablo Bruhlmann S, del Pozo ML et al (2008) Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit. Clin Neuropharmacol 31:319\u2013332","journal-title":"Clin Neuropharmacol"},{"key":"4445_CR23","doi-asserted-by":"crossref","unstructured":"Leucht S (2014) Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry 75 Suppl 1: 8\u201314","DOI":"10.4088\/JCP.13049su1c.02"},{"key":"4445_CR24","unstructured":"Leucht S, Heres S (2006) Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 67 Suppl 5: 3\u20138"},{"key":"4445_CR25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","volume":"79","author":"S Leucht","year":"2005","unstructured":"Leucht S, Kane JM, Kissling W et al (2005) What does the PANSS mean? Schizophr Res 79:231\u2013238","journal-title":"Schizophr Res"},{"key":"4445_CR26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","volume":"127","author":"C Leucht","year":"2011","unstructured":"Leucht C, Heres S, Kane JM et al (2011) Oral versus depot antipsychotic drugs for schizophrenia\u2014a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127:83\u201392","journal-title":"Schizophr Res"},{"key":"4445_CR27","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951\u2013962","journal-title":"Lancet"},{"key":"4445_CR28","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"key":"4445_CR29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1055\/s-2004-834786","volume":"44","author":"M Linden","year":"2005","unstructured":"Linden M, Baron S (2005) The \u201cMini-ICF-Rating for Mental Disorders (Mini-ICF-P)\u201d. A short instrument for the assessment of disabilities in mental disorders. Die Rehabilitation 44:144\u2013151","journal-title":"Die Rehabilitation"},{"key":"4445_CR30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1741-7015-3-21","volume":"3","author":"H Liu-Seifert","year":"2005","unstructured":"Liu-Seifert H, Adams DH, Kinon BJ (2005) Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 3:21","journal-title":"BMC Med"},{"key":"4445_CR31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.psychres.2007.07.012","volume":"161","author":"P-M Llorca","year":"2008","unstructured":"Llorca P-M (2008) Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 161:235\u2013247","journal-title":"Psychiatry Res"},{"key":"4445_CR32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004850-200505000-00001","volume":"20","author":"H-J M\u00f6ller","year":"2005","unstructured":"M\u00f6ller H-J, Llorca P-M, Sacchetti E et al (2005) Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 20:121\u2013130","journal-title":"Int Clin Psychopharmacol"},{"key":"4445_CR33","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00127-012-0604-8","volume":"48","author":"A Molodynski","year":"2013","unstructured":"Molodynski A, Linden M, Juckel G et al (2013) The reliability, validity, and applicability of an English language version of the Mini-ICF-APP. Soc Psychiatry Psychiatr Epidemiol 48:1347\u20131354","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"4445_CR34","doi-asserted-by":"crossref","unstructured":"Morosini PL, Magliano L, Brambilla L et al (2000) Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 101: 323\u20139","DOI":"10.1034\/j.1600-0447.2000.101004323.x"},{"key":"4445_CR35","doi-asserted-by":"crossref","unstructured":"Naber D, Lambert M (2009) The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS drugs 23:649\u2013659","DOI":"10.2165\/00023210-200923080-00002"},{"key":"4445_CR36","unstructured":"National Institute for Health and Care Excellence (NICE) (2014) Psychosis and schizophrenia in adults: treatment and management (CG178)"},{"key":"4445_CR37","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1185\/03007990903149306","volume":"25","author":"JM Olivares","year":"2009","unstructured":"Olivares JM, Peuskens J, Pecenak J et al (2009a) Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 25:2197\u20132206","journal-title":"Curr Med Res Opin"},{"key":"4445_CR38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.eurpsy.2008.12.002","volume":"24","author":"JM Olivares","year":"2009","unstructured":"Olivares JM, Rodriguez-Morales A, Diels J et al (2009b) Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 24:287\u2013296","journal-title":"Eur Psychiatry"},{"key":"4445_CR39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","volume":"30","author":"GJ Pandina","year":"2010","unstructured":"Pandina GJ, Lindenmayer J-P, Lull J et al (2010) A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 30:235\u2013244","journal-title":"J Clin Psychopharmacol"},{"key":"4445_CR40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","volume":"56","author":"D Robinson","year":"1999","unstructured":"Robinson D, Woerner MG, Alvir JM et al (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241\u2013247","journal-title":"Arch Gen Psychiatry"},{"key":"4445_CR41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/11599080-000000000-00000","volume":"32","author":"F Rosa","year":"2012","unstructured":"Rosa F, Schreiner A, Thomas P et al (2012) Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clin Drug Investig 32:267\u2013279","journal-title":"Clin Drug Investig"},{"key":"4445_CR42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","volume":"123","author":"C Rummel-Kluge","year":"2010","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S et al (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123:225\u2013233","journal-title":"Schizophr Res"},{"key":"4445_CR43","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.clinthera.2014.08.014","volume":"36","author":"A Schreiner","year":"2014","unstructured":"Schreiner A, Bergmans P, Cherubin P et al (2014a) A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents. Clin Ther 36:1372\u201388.e1","journal-title":"Clin Ther"},{"key":"4445_CR44","doi-asserted-by":"crossref","unstructured":"Schreiner A, Svensson A, Wapenaar R et al (2014b) Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study World J Biol Psychiatry 15:534\u2013545","DOI":"10.3109\/15622975.2014.902990"},{"key":"4445_CR45","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","volume":"169","author":"A Schreiner","year":"2015","unstructured":"Schreiner A, Aadamsoo K, Altamura AC et al (2015a) Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res 169:393\u2013399","journal-title":"Schizophr Res"},{"key":"4445_CR46","doi-asserted-by":"crossref","unstructured":"Schreiner A, Bergmans P, Cherubin P et al (2015b) Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics. J Psychopharmacol (Oxford, England) 29: 910\u201322","DOI":"10.1177\/0269881115586284"},{"key":"4445_CR47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.schres.2005.12.857","volume":"84","author":"R Tandon","year":"2006","unstructured":"Tandon R, Marcus RN, Stock EG et al (2006) A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 84:77\u201389","journal-title":"Schizophr Res"},{"key":"4445_CR48","unstructured":"Taylor D, Paton C, Kapur S (2012) The Maudsley prescribing guidelines in psychiatry, 11th edn. Wiley-Blackwell"},{"key":"4445_CR49","doi-asserted-by":"crossref","unstructured":"Tiihonen J, Haukka J, Taylor M et al (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603\u2013609","DOI":"10.1176\/appi.ajp.2011.10081224"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-016-4445-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-016-4445-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-016-4445-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T09:12:10Z","timestamp":1568538730000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-016-4445-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,5]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["4445"],"URL":"https:\/\/doi.org\/10.1007\/s00213-016-4445-0","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,5]]}}}